Lamisil, FDA-Approved for Pediatric Treatment of Scalp Ringworm

Filed in archive FDA Approvals , Kid's Health , Treatment on September 30, 2007

We know Lamisil Tablets as a treatment for nail fungus infection (onychomycosis) whose generic versions have been approved by the FDA in July of this year.

Now, the FDA has just approved Lamisil Oral Granules for the treatment of tinea capitis (a fungal infection of the scalp) in children aged 4 and older.

Tinea capitis most commonly affects children and is often characterized by severe itching, dandruff and bald patches. It is a persistent and contagious fungal infection that usually does not respond to topical treatment.

The FDA, in a pediatric written request, approached Novartis Pharmaceuticals Corporation of East Hanover, N.J., the manufacturer of Lamisil (terbinafine hydrochloride), for a formulation palatable for children. The company formulated the new dosage form, granules, which can be sprinkled on food.

Lamisil Oral Granules (whose actual dosage amount will be based on the child's weight) are approved to be administered once a day for six weeks and is a product of Novartis Pharmeceuticals Corporation.

Source: FDA News

[Photo Credit: pediatrics.about.com]